Rigor-led Discovery

Rigor-led development of next-generation therapeutics for HIV and cancer. At Masinova, I combine Quality-by-Design (QbD) execution with modality innovation—spanning next-generation CAR T-cell engineering and  nanoparticles (including targeted nanoparticle approaches). My goal is to build reproducible, safety-informed, development-ready programs that can progress efficiently from preclinical milestones toward clinical evaluation.

 

My Scientific Approach

HIV Pathogenesis, Immune Evasion, and AI/ML

SOP-driven workflows and qualified/robust assays to support decisions.

A founder-authored review synthesizing key mechanisms of HIV entry, immune deregulation, latency, immuno-therapeutic strategies, and emerging AI/ML applications relevant to cure-oriented research.

Beyond the ordinary: Core Technology Building

This is where my journey begins.

TPP-defined HIV program.
The lead HIV program is guided by a defined Target Product Profile (TPP) and a structured development plan designed to support Phase I readiness.

Early oncology programs in development.
I am advancing early-stage oncology programs using the same rigor-led, QbD-driven framework.

Driven by passion: Next-Gen CAR T cell

Next-Generation CAR T-Cell

Engineering durable cellular therapies for HIV and oncology.
Masinova designs next-generation CAR T-cell strategies to address key biological barriers such as persistence, specificity, and escape/heterogeneity. In HIV, we focus on durable immune control and resistance to viral diversity; in oncology, we focus on overcoming antigen heterogeneity and tumor microenvironment suppression. Program-level construct details are available under NDA.

Design priorities

 

  • Multi-parameter specificity and functional potency

  • Persistence and controlled activation

  • Escape-resilience and safety logic

 

 

Focus on Medical Needs: NanoParticle

AI-Integrated Nanomedicine (Targeted Nanoparticles)

Precision delivery to improve tissue access and therapeutic index.
I develop targeted nanomedicine strategies using nanoparticle design principles to optimize biodistribution, target engagement, and exposure in hard-to-reach tissues. Our development work is guided by structured criteria (e.g., size/charge/stability, targeting ligand design, release kinetics) and evaluated using reproducible test frameworks aligned to translational endpoints.

What I optimize

 

  • Delivery precision and tissue penetration

  • Stability, release kinetics, and PK/PD alignment

  • Safety-informed design and developability

 

 

Quality and Speed

Translational Intelligence Framework

Connecting preclinical signals to clinical readiness with QbD discipline.
Masinova applies structured translational thinking tools—including simulation-driven and decision frameworks—to connect TPP-defined goals to qualified assays, biomarkers, and development gates. This framework supports clear go/no-go criteria, early risk identification, and partner-ready packages that improve efficiency from preclinical development toward Phase I readiness.

How it shows up

 

  • TPP → assays → biomarkers → decision gates

  • Safety-by-design and risk mitigation planning

  • Partner-evaluable preclinical package (under NDA)

 

 

Partner-Ready Preclinical Package

Masinova has built a complete, QbD-driven preclinical package for our lead HIV/oncology program. This package links a clear Target Product Profile (TPP) to qualified assays, defined go/no-go criteria, and an IND-enabling plan. Potential partners can confidently evaluate the assets under NDA.